Cargando…

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis

BACKGROUND AND AIM: This study aimed to determine the efficacy and safety of vedolizumab treatment with or without concomitant immunomodulator use in Japanese patients with moderate‐to‐severe ulcerative colitis. METHODS: Among enrolled patients in a phase 3 study conducted in Japan (clinicaltrials.g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naganuma, Makoto, Watanabe, Kenji, Motoya, Satoshi, Ogata, Haruhiko, Matsui, Toshiyuki, Suzuki, Yasuo, Ursos, Lyann, Sakamoto, Shigeru, Shikamura, Mitsuhiro, Hori, Tetsuharu, Fernandez, Jovelle, Watanabe, Mamoru, Hibi, Toshifumi, Kanai, Takanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293068/ https://www.ncbi.nlm.nih.gov/pubmed/34409654 http://dx.doi.org/10.1111/jgh.15667

Ejemplares similares

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
por: Watanabe, Kenji, et al.
Publicado: (2019)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2021)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2014)

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
por: Hisamatsu, Tadakazu, et al.
Publicado: (2021)

Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
por: Naganuma, Makoto, et al.
Publicado: (2017)

Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission
por: Hisamatsu, Tadakazu, et al.
Publicado: (2015)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Effects of the Oral Administration of Mosapride Citrate on Capsule Endoscopy Completion Rate
por: Ida, Yosuke, et al.
Publicado: (2012)

Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
por: Naganuma, Makoto, et al.
Publicado: (2019)

Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network)
por: Yamazaki, Hajime, et al.
Publicado: (2019)

Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capsule endoscopy: SCHEMA study
por: Hosoe, Naoki, et al.
Publicado: (2016)

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan
por: Komoto, Shunsuke, et al.
Publicado: (2016)

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan
por: Ueno, Fumiaki, et al.
Publicado: (2012)

Recent trends in diagnostic techniques for inflammatory bowel disease
por: Naganuma, Makoto, et al.
Publicado: (2015)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
por: Ogata, Haruhiko, et al.
Publicado: (2017)

Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
por: Hibi, Toshifumi, et al.
Publicado: (2020)

5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2018)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
por: Haga, Keiichi, et al.
Publicado: (2022)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab
por: Sandhu, Sunny, et al.
Publicado: (2022)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Evidence-based clinical practice guidelines for inflammatory bowel disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Role of Immunomodulation of BCG Therapy on AML Remission
por: Kennedy, Alice, et al.
Publicado: (2021)

Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
por: Takatsu, Noritaka, et al.
Publicado: (2020)

Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy
por: Takayama, Tetsuro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n7m1r6oklv347ad0uu24ker747